DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gianni L, Pienkowski T, Im YH. et al.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol 2016;
17: 791-800
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.